ELAN earnings

Raising Full Year Outlook and Innovation Target, Improving Year-End Net Leverage Ratio TargetFirst Quarter 2026 Financial Results:Revenue of $1,371 million, an increase of 15% year-over-year; 10% organic constant currency growthReported Net Income of $57 million, Adjusted Net Income of $204 millionAdjusted EBITDA of $334 million; Adjusted EBITDA Margin of 24.5%Reported EPS of $0.11, Adjusted EPS of $0.40Net leverage ratio of 3.5x Adjusted EBITDAFull Year 2026 Guidance:Raising innovation revenue target to $1.2 billionRaising revenue guidance to $5,010 million to $5,085 million, or 5% to 7% organic constant currency growthRaising Adjusted EBITDA to $975 million to $1,005 million, a year-over-y

INDIANAPOLIS, April 16, 2026 /PRNewswire/ -- Elanco Animal Health Incorporated (NYSE:ELAN) will announce its first quarter 2026 financial results on Wednesday, May 6, 2026. Elanco will also conduct a conference call on that day with the investment community and media to further detail the company's performance. The conference call will begin at 8:00 a.m. Eastern time. Investors, media, and the general public can access a live webcast of the conference call through the link that will be posted on Elanco's website at https://investor.elanco.com/events-and-presentations/default.asp

Raising 2026 Innovation Target; Full Year 2026 Guidance of 4%-6% Organic Constant Currency Revenue Growth, 6%-9% Adjusted EBITDA Growth In Line with Investor Day OutlookFourth Quarter 2025 Financial Results:Revenue of $1,144 million, increased 12% on a reported basis; 9% in organic constant currencyReported Net Loss of $276 million, Adjusted Net Income of $64 millionAdjusted EBITDA of $189 million; Adjusted EBITDA Margin of 16.7%Reported EPS of $(0.56), Adjusted EPS of $0.13Full Year 2025 Financial Results:Exceeded innovation revenue target at $892 million; delivered all 'Big 6' blockbuster potential products by the end of 2025 with Befrena approval in Q4 2025Revenue of $4,715 million, incre

INDIANAPOLIS, Jan. 22, 2026 /PRNewswire/ -- Elanco Animal Health Incorporated (NYSE:ELAN) will announce its fourth quarter and full year 2025 financial results on Tuesday, February 24, 2026. Elanco will also conduct a conference call on that day with the investment community and media to further detail the company's performance. The conference call will begin at 8:00 a.m. Eastern Standard Time. Investors, media, and the general public can access a live webcast of the conference call through the link that will be posted on Elanco's website at https://investor.elanco.com/events-

GREENFIELD, Ind., Oct. 1, 2025 /PRNewswire/ -- Elanco Animal Health Incorporated (NYSE:ELAN) will announce its third quarter 2025 financial results on Wednesday, November 5, 2025. Elanco will also conduct a conference call on that day with the investment community and media to further detail the company's performance. The conference call will begin at 8:00 a.m. eastern time. Investors, media, and the general public can access a live webcast of the conference call through the link that will be posted on Elanco's website at https://investor.elanco.com/events-and-presentations/de

Raising Full Year Outlook and Innovation Target, Improving Year-End Net Leverage Ratio Target Second Quarter 2025 Financial Results:Revenue of $1,241 million, an increase of 5% year-over-year; 8% organic constant currency growthReported Net Income of $11 million, Adjusted Net Income of $131 millionAdjusted EBITDA of $238 million; Adjusted EBITDA Margin of 19.2% Reported EPS of $0.02, Adjusted EPS of $0.26Net leverage ratio of 4.0x Adjusted EBITDAFull Year 2025 Guidance:Raising revenue guidance to $4,570 to $4,620 million; expect accelerating organic constant currency revenue growth of 5% to 6% vs. 3% in 2024Raising 2025 innovation revenue target by $60 million to $720 to $800 millionReported

GREENFIELD, Ind., July 10, 2025 /PRNewswire/ -- Elanco Animal Health Incorporated (NYSE:ELAN) will announce its second quarter 2025 financial results on Thursday, August 7, 2025. Elanco will also conduct a conference call on that day with the investment community and media to provide further details about the company's performance. The conference call will begin at 8:00 a.m. Eastern time. Investors, media, and the general public can access a live webcast of the conference call through the link posted on Elanco's website at https://investor.elanco.com/events-and-presentations/d

Accelerating Debt Paydown in 2025 First Quarter 2025 Financial Results:Revenue of $1,193 million, a decline of 1% year-over-year; 4% organic constant currency growthReported Net Income of $67 million, Adjusted Net Income of $184 millionAdjusted EBITDA of $276 million, or 23.1% of RevenueReported EPS of $0.13, Adjusted EPS of $0.37Net leverage ratio of 4.4x Adjusted EBITDAFull Year 2025 Guidance:Raising revenue guidance to $4,510 to $4,580 million, with $65 to $70 million increase since February driven by foreign exchange tailwind; continue to expect accelerating organic constant currency revenue growth to mid-single digitsRaising 2025 innovation revenue target to $660 to $740 millionReported

GREENFIELD, Ind., April 10, 2025 /PRNewswire/ -- Elanco Animal Health Incorporated (NYSE:ELAN) will announce its first quarter 2025 financial results on Wednesday, May 7, 2025. Elanco will also conduct a conference call on that day with the investment community and media to further detail the company's performance. The conference call will begin at 8:00 a.m. eastern time. Investors, media, and the general public can access a live webcast of the conference call through the link that will be posted on Elanco's website at https://investor.elanco.com/events-and-presentations/defau

GREENFIELD, Ind., Feb. 4, 2025 /PRNewswire/ -- Elanco Animal Health Incorporated (NYSE:ELAN) will announce its fourth quarter and full year 2024 financial results on Tuesday, February 25, 2025. Elanco will also conduct a conference call on that day with the investment community and media to further detail the company's performance. The conference call will begin at 8:00 a.m. eastern time. Investors, media, and the general public can access a live webcast of the conference call through the link that will be posted on Elanco's website at https://investor.elanco.com/events-and-pr

GREENFIELD, Ind., Oct. 10, 2024 /PRNewswire/ -- Elanco Animal Health Incorporated (NYSE:ELAN) will announce its third quarter 2024 financial results on Thursday, November 7, 2024. Elanco will also conduct a conference call on that day with the investment community and media to further detail the company's performance. The conference call will begin at 8:00 a.m. eastern time. Investors, media, and the general public can access a live webcast of the conference call through the link that will be posted on Elanco's website at https://investor.elanco.com/events-and-presentations/de

U.S. Food and Drug Administration approves Zenrelia, a once-daily oral JAK inhibitor for dogs with allergic and atopic dermatitisElanco enters the estimated $1.7 billion global canine dermatology market, highly accretive to existing portfolioIn a head-to-head study, Zenrelia was shown to be at least as effective as the market incumbent JAK inhibitor at the primary end point, with an additional endpoint at which Zenrelia got 77% of dogs to clinical remission of itch, compared to 53% of dogs treated with Apoquel® (oclacitinib tablet)1*Zenrelia launch begins in U.S. with Elanco now taking orders; product expected to ship in coming daysGREENFIELD, Ind., Sept. 19, 2024 /PRNewswire/ -- Elanco Anim

GREENFIELD, Ind., July 18, 2024 /PRNewswire/ -- Elanco Animal Health Incorporated (NYSE:ELAN) will announce its second quarter 2024 financial results on Thursday, August 8, 2024. Elanco will also conduct a conference call on that day with the investment community and media to further detail the company's performance. The conference call will begin at 8:00 a.m. eastern time. Investors, media, and the general public can access a live webcast of the conference call through the link that will be posted on Elanco's website at https://investor.elanco.com/events-and-presentations/def

First Quarter 2024 Financial ResultsRevenue of $1,205 millionReported Net income of $32 million, Adjusted Net income of $167 millionAdjusted EBITDA of $294 million, or 24.4% of RevenueReported EPS of $0.06, Adjusted EPS of $0.34 Net leverage ratio of 6.1x Adjusted EBITDAYear over year growth rates are meaningfully impacted by a shift in customer purchasing related to the ERP Blackout in 2023, with an estimated $90 to $110 million of revenue shift from the second quarter of 2023 into the first quarter of 2023Updating full year 2024 financial guidance to reflect first quarter outperformance offset by expected unfavorable impact of foreign exchange rates:Revenue of $4,460 to $4,515 million, con

GREENFIELD, Ind., April 17, 2024 /PRNewswire/ -- Elanco Animal Health Incorporated (NYSE:ELAN) will announce its first quarter 2024 financial results on Wednesday, May 8, 2024. Elanco will also conduct a conference call on that day with the investment community and media to further detail the company's performance. The conference call will begin at 8:00 a.m. eastern time. Investors, media, and the general public can access a live webcast of the conference call through the link that will be posted on Elanco's website at https://investor.elanco.com/events-and-presentations/defau

GREENFIELD, Ind., Feb. 8, 2024 /PRNewswire/ -- Elanco Animal Health Incorporated (NYSE:ELAN) will announce its fourth quarter and full year 2023 financial results on Monday, February 26, 2024. Elanco will also conduct a conference call on that day with the investment community and media to further detail the company's performance. The conference call will begin at 8:00 a.m. eastern time. Investors, media, and the general public can access a live webcast of the conference call through the link that will be posted on Elanco's website on our events and presentations page. A repla

Elanco Animal Health Incorporated (NYSE:ELAN) will announce its third quarter 2023 financial results on Tuesday, November 7, 2023. Elanco will also conduct a conference call on that day with the investment community and media to further detail the company's performance. The conference call will begin at 8:00 a.m. eastern time. Investors, media, and the general public can access a live webcast of the conference call through the link that will be posted on Elanco's website on our events and presentations page. A replay will also be available on the website shortly following the call. ABOUT ELANCO Elanco Animal Health Incorporated (NYSE:ELAN) is a global leader in animal health dedicated

Elanco Animal Health Incorporated (NYSE:ELAN) will announce its second quarter 2023 financial results on Monday, August 7, 2023. Elanco will also conduct a conference call on that day with the investment community and media to further detail the company's performance. The conference call will begin at 8:00 a.m. eastern time. Investors, media, and the general public can access a live webcast of the conference call through the link that will be posted on Elanco's website on our events and presentations page. A replay will also be available on the website shortly following the call. ABOUT ELANCO Elanco Animal Health Incorporated (NYSE:ELAN) is a global leader in animal health dedicated t

First Quarter 2023 Financial Results Revenue of $1,257 million, including an estimated $90-$110 million benefit from customer purchasing shifted from the second quarter into the first as a result of ERP system commercial ordering blackout period for legacy Bayer Animal Health products in April Reported Net Income of $103 million, Adjusted Net Income of $220 million Adjusted EBITDA of $379 million or 30.2% of Revenue Reported EPS of $0.21, Adjusted EPS of $0.45 Net leverage ratio of 5.4x Adjusted EBITDA Raising the bottom end of full year 2023 guidance ranges to reflect current assumptions: Revenue of $4,310 to $4,400 million Reported Net Loss of $(134) to $(98) mil

Elanco Animal Health Incorporated (NYSE:ELAN) will announce its first quarter 2023 financial results on Tuesday, May 9, 2023. Elanco will also conduct a conference call on that day with the investment community and media to further detail the company's performance. The conference call will begin at 8:00 a.m. eastern time. Investors, media, and the general public can access a live webcast of the conference call through the link that will be posted on Elanco's website at https://investor.elanco.com/events-and-presentations/default.aspx. A replay will also be available on the website shortly following the call. ABOUT ELANCO Elanco Animal Health Incorporated (NYSE:ELAN) is a global leader

Fourth Quarter 2022 Financial Results: Revenue of $988 million Reported Net Loss of $54 million, Adjusted Net Income of $95 million Adjusted EBITDA of $174 million or 17.6% of Revenue Reported EPS of $(0.11), Adjusted EPS of $0.19 Net leverage ratio of 5.4x Adjusted EBITDA Full Year 2022 Financial Results: Revenue of $4,418 million Reported Net Loss of $74 million, Adjusted Net Income of $548 million Adjusted EBITDA of $1,023 million or 23.2% of Revenue Reported EPS of $(0.15), Adjusted EPS of $1.11 Full Year 2023 Guidance: Revenue of $4,280 to $4,400 million Reported Net Loss of $(157) to $(109) million, Adjusted EBITDA of $920 to $1,000 million Reported EP

Elanco Animal Health Incorporated (NYSE:ELAN) will announce its fourth quarter and full year 2022 financial results on Tuesday, February 21, 2023. Elanco will also conduct a conference call on that day with the investment community and media to further detail the company's performance. The conference call will begin at 8:00 a.m. eastern time. Investors, media, and the general public can access a live webcast of the conference call through the link that will be posted on Elanco's website at https://investor.elanco.com/events-and-presentations/default.aspx. A replay will also be available on the website shortly following the call. ABOUT ELANCO Elanco Animal Health Incorporated (NYSE:ELAN)

Third Quarter 2022 Financial Results Revenue of $1,028 million Reported Net Loss of $49 million, Adjusted Net Income of $96 million Adjusted EBITDA of $205 million or 19.9% of Revenue Reported EPS of $(0.10), Adjusted EPS of $0.20 Net leverage ratio decreased to 5.2x Adjusted EBITDA Updating full year 2022 guidance to reflect current assumptions: Revenue of $4,385 to $4,430 million Reported Net Loss of $(82) to $(57) million, Reported diluted EPS of $(0.17) to $(0.12) Adjusted EPS of $1.01 to $1.07, Adjusted EBITDA of $1,010 to $1,045 million Net leverage ratio expected at 5.2x to 5.3x Adjusted EBITDA at year-end 2022 Initiated submission for broad spectrum parasi

Elanco Animal Health Incorporated (NYSE:ELAN) will announce its third quarter 2022 financial results on Tuesday, November 8, 2022. Elanco will also conduct a conference call on that day with the investment community and media to further detail the company's performance. The conference call will begin at 8:00 a.m. eastern time. Investors, media, and the general public can access a live webcast of the conference call through the link that will be posted on Elanco's website at https://investor.elanco.com/events-and-presentations/default.aspx. A replay will also be available on the website shortly following the call. ABOUT ELANCO Elanco Animal Health Incorporated (NYSE:ELAN) is a global lead

Second Quarter 2022 Financial Results Revenue of $1,177 million Reported Net Loss of $22 million, Adjusted Net Income of $177 million Adjusted EBITDA of $300 million or 25.5% of Revenue Reported EPS of $(0.04), Adjusted EPS of $0.36 Updating full year 2022 guidance to reflect current assumptions related to economic, environmental and company-specific factors impacting the business, expecting: Revenue of $4,465 to $4,550 million Reported diluted EPS of $(0.10) to $(0.03), Adjusted EPS of $1.06 to $1.13 Reported Net Loss of $(48) to $(15) million, Adjusted EBITDA of $1,060 to $1,100 million Providing financial guidance for the third quarter 2022, expecting: Revenue of

Elanco Animal Health Incorporated (NYSE:ELAN) will announce its second quarter 2022 financial results on Monday, August 8, 2022. Elanco will also conduct a conference call on that day with the investment community and media to further detail the company's performance. The conference call will begin at 8:00 a.m. eastern time. Investors, media, and the general public can access a live webcast of the conference call through the link that will be posted on Elanco's website at https://investor.elanco.com/events-and-presentations/default.aspx. A replay will also be available on the website shortly following the call. ABOUT ELANCO Elanco Animal Health Incorporated (NYSE:ELAN) is a global leader

First Quarter 2022 Financial Results Revenue of $1,225 million Reported Net Income of $48 million, Adjusted Net Income of $177 million Adjusted EBITDA of $339 million or 27.7% of Revenue Reported EPS of $0.10, Adjusted EPS of $0.36 Updating full year 2022 revenue guidance to be $4,700 to $4,755 million, due to the negative impact of foreign exchange rates; constant currency revenue growth guidance remains unchanged. Increasing guidance for full year 2022 diluted EPS to $0.02 to $0.09 on a reported basis and updating guidance to $1.15 to $1.21 on an adjusted basis, due to the negative impact of foreign exchange rates. Providing financial guidance for the second quarter 2022

Elanco Animal Health Incorporated (NYSE:ELAN) will announce its first quarter 2022 financial results on Monday, May 9, 2022. Elanco will also conduct a conference call on that day with the investment community and media to further detail the company's performance. The conference call will begin at 8:00 a.m. eastern time. Investors, media, and the general public can access a live webcast of the conference call through the link that will be posted on Elanco's website at https://investor.elanco.com/events-and-presentations/default.aspx. A replay will also be available on the website shortly following the call. ABOUT ELANCO Elanco Animal Health Incorporated (NYSE:ELAN) is a global leader in

Full year 2021 revenue was $4,765 million, an increase of 46 percent, including $1,311 million of incremental revenue from Bayer Animal Health products in 2021. Full year 2021 earnings per share (EPS) was $(0.97) (reported), or $1.05 (adjusted). Fourth quarter 2021 revenue was $1,113 million, a decline of 2 percent. Excluding the unfavorable impact of $60 million of previously disclosed items that benefited the fourth quarter of 2020 and the unfavorable impact of foreign exchange rates, fourth quarter 2021 revenue increased 4 percent. Fourth quarter 2021 EPS was $(0.20) (reported), or $0.21 (adjusted), an increase of 70 percent as reported and 75 percent on an adjusted basis. Providing

Elanco Animal Health Incorporated (NYSE:ELAN) will announce its fourth quarter and full year 2021 financial results on Thursday, February 24, 2022. Elanco will also conduct a conference call on that day with the investment community and media to further detail the company's performance. The conference call will begin at 8:00 a.m. eastern time. Investors, media, and the general public can access a live webcast of the conference call through the link that will be posted on Elanco's website at https://investor.elanco.com/events-and-presentations/default.aspx. A replay will also be available on the website shortly following the call. ABOUT ELANCO Elanco Animal Health Incorporated (NYSE:ELAN)

Third quarter revenue increased 27 percent, benefiting from increased scale and diversification with the addition of Bayer Animal Health. On a pro forma combined company basis, Elanco's revenue grew approximately 6 percent, assuming the Bayer Animal Health acquisition had occurred on January 1, 2020. Third quarter revenue was $1,131 million, exceeding the midpoint of guidance by $44 million, due to strength in the global Farm Animal business and global Pet Health retail. Gross margin improved 530 basis points year over year to 55.6 percent on a reported basis, and 150 basis points to 55.7 percent on an adjusted basis. Reported earnings per share (EPS) was $(0.21), and adjusted EPS wa

Elanco Animal Health Incorporated (NYSE:ELAN) will announce its third quarter 2021 financial results on Friday, November 5, 2021. Elanco will also conduct a conference call on that day with the investment community and media to further detail the company's performance. The conference call will begin at 8:00 a.m. eastern time. Investors, media, and the general public can access a live webcast of the conference call through the link that will be posted on Elanco's website at https://investor.elanco.com/events-and-presentations/default.aspx. A replay will also be available on the website shortly following the call. ABOUT ELANCO Elanco Animal Health Incorporated (NYSE:ELAN) is a global leade

Exceeded second quarter 2021 guidance; Increasing full year 2021 revenue outlook  Revenue in the second quarter was $1,279 million, comprised of $750 million from the legacy Elanco portfolio and $529 million from the legacy Bayer Animal Health portfolio. Gross margin was 56.9% on a reported basis and 57.0% on an adjusted basis, benefiting from the addition of the Bayer Animal Health portfolio and continued productivity improvements. Earnings per share (EPS) was $(0.43) (reported), or $0.28 (adjusted), including an approximate $0.03 negative impact from discrete tax items to adjusted EPS compared to guidance. Updating financial guidance for the full year 2021 with revenue of $4,680